Bendamustine
- Generic Name
- Bendamustine
- Brand Names
- Belrapzo, Bendeka, Treanda, Vivimusta
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21Cl2N3O2
- CAS Number
- 16506-27-7
- Unique Ingredient Identifier
- 9266D9P3PQ
- Background
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophili...
- Indication
Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
- Associated Therapies
- -
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
- Conditions
- Nodal Marginal Zone B-cell LymphomaPeripheral T-cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Hodgkin LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic Lymphoma
- Interventions
- First Posted Date
- 2010-04-26
- Last Posted Date
- 2017-05-24
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 43
- Registration Number
- NCT01110135
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)
- Conditions
- Interventions
- First Posted Date
- 2010-04-22
- Last Posted Date
- 2012-08-28
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 50
- Registration Number
- NCT01108341
- Locations
- 🇺🇸
Florida Cancer Institute - New Hope, New Port Richey, Florida, United States
🇺🇸Dublin Hematology Oncology Care P.C., Dublin, Georgia, United States
🇺🇸Cancer Care and Hematology Specialists of Chicagoland, Niles, Illinois, United States
Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2010-03-31
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT01096992
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
- First Posted Date
- 2010-03-18
- Last Posted Date
- 2016-05-23
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT01088984
- Locations
- 🇺🇸
Teva Investigational Site 15, New York, New York, United States
🇺🇸Teva Investigational Site 17, Orange, California, United States
🇺🇸Teva Investigational Site 12, San Diego, California, United States
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
- First Posted Date
- 2010-03-17
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 241
- Registration Number
- NCT01088048
- Locations
- 🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇺🇸Willamette Valley Cancer Institute and Research Center, Springfield, Oregon, United States
🇺🇸Clearview Cancer Institute, Huntsville, Alabama, United States
Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
- Conditions
- Interventions
- First Posted Date
- 2010-02-23
- Last Posted Date
- 2014-04-24
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 54
- Registration Number
- NCT01073163
- Locations
- 🇺🇸
Geisinger Medical Center, Danville, Pennsylvania, United States
🇺🇸The Hospital of Central Connecticut, New Britain, Connecticut, United States
🇺🇸Hematology Oncology Physicans Extenders Group, Tucson, Arizona, United States
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 69
- Registration Number
- NCT01059786
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 413
- Registration Number
- NCT01059630
- Locations
- 🇺🇸
South Texas Inst of Cancer, Corpus Christi, Texas, United States
🇺🇸University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)
- Conditions
- Interventions
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 357
- Registration Number
- NCT01056510
Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2017-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 59
- Registration Number
- NCT01056276
- Locations
- 🇺🇸
Hematology Oncology Clinic, LLP, Baton Rouge, Louisiana, United States
🇺🇸Los Robles Hospital and Medical Center, Thousand Oaks, California, United States
🇺🇸Florida Cancer Specialists, Ft. Myers, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.